Nuvo Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was CAD 54.71 million compared to CAD 51.2 million a year ago. Net income was CAD 20.76 million compared to net loss of CAD 26.61 million a year ago. Basic earnings per share from continuing operations was CAD 1.82 compared to basic loss per share from continuing operations of CAD 2.34 a year ago. Diluted earnings per share from continuing operations was CAD 0.42 compared to diluted loss per share from continuing operations of CAD 2.34 a year ago.